

TABLE OF CONTENTS

PREFACE.....	xi
--------------	----

PART I

GLOBALIZATION AND ACCESS TO DRUGS: IMPLICATIONS OF THE WTO/TRIPS AGREEMENT	1
---	----------

EXECUTIVE SUMMARY	1
-------------------------	---

INTRODUCTION	5
--------------------	---

1. BRIEF HISTORICAL BACKGROUND TO THE INTERNATIONAL TRADING SYSTEM.....	7
--	---

1.1 The Simultaneous Creation of the GATT, the IMF and the World Bank.....	7
---	---

1.2 The Objectives, Nature and Functioning of the GATT	8
<i>Objectives</i>	8
<i>Nature</i>	8
<i>Obligations of the contracting parties</i>	9
<i>The "Rounds"</i>	9

1.3 The Uruguay Round and the Creation of the WTO: The New Global Economic Environment	10
<i>Long and difficult negotiations</i>	11
<i>The results of the Uruguay Round: strengthening and enlargement of the multilateral trade system</i>	12
<i>How does the WTO differ from the GATT?</i>	14

1.4 The Protection of Intellectual Property Rights before the WTO.....	15
---	----

2. READING THE TRIPS AGREEMENT	
FROM THE PERSPECTIVE OF ACCESS TO DRUGS.....	17
2.1 General Presentation of the Agreement.....	17
2.2 Fundamental Principles and Objectives of the Agreement: The Necessary Balance between Intellectual Property and Accessibility	18
2.3 Patents for Pharmaceutical Products and Processes available All Over the World.....	21
2.4 Non-patentable Inventions: Biotechnology Inventions	23
2.5 Effects of Protection: A Monopoly of Working for 20 years.....	25
Article 28: Rights conferred.....	26
Attenuation of the monopoly through exhaustion of rights.....	26
Strengthening the monopoly through the patenting of processes.....	29
Extension of the duration of the monopoly.....	32
2.6 Application of the TRIPS Agreement	32
For industrialized countries: 1996.....	34
For developing countries: 2000 or 2005.....	35
For least-developed countries: 2006.....	36
2.7 During the Transitional Period.....	36
Establishment of a "mail-box" in 1995.....	36
Possibility of exclusive marketing rights.....	38
What happens to existing patents?.....	40
2.8 How Can the Monopoly be Limited?	42
Exceptions	43
Article 7: Objectives.....	44
Article 8: Principles	44
Compulsory Licences	45

3. CONCLUSIONS: ISSUES AT STAKE AND CONSTRAINTS ON ACCESS TO DRUGS.....	51
3.1 The Drug Patents Debate.....	51
3.2 Some Recommendations	54
DEFINITIONS AND TERMINOLOGY	57
SELECTED BIBLIOGRAPHY	69

PART II

THE PHARMACEUTICAL INDUSTRY, US GOVERNMENT AND WTO CRITIQUES OF WHO'S "GLOBALIZATION AND ACCESS TO DRUGS: IMPLICATIONS OF THE WTO/TRIPS AGREEMENT"

91

1. A CRITIQUE OF WHO DAP SERIES NUMBER 7 "GLOBALIZATION AND ACCESS TO DRUGS: IMPLICATIONS OF THE TRIPS AGREEMENT" <i>AN ANALYSIS SUBMITTED BY THE PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA</i>	94
2. LETTER FROM ADRIAN OTTEN, DIRECTOR OF INTELLECTUAL PROPERTY AND INVESTMENT DIVISION OF THE WTO TO DR. JONATHAN D. QUICK, DIRECTOR, ACTION PROGRAMME ON ESSENTIAL DRUGS, WHO	114
3. A CRITIQUE FROM THE U.S. GOVERNMENT EXPRESSED THROUGH FDA – "GLOBALIZATION AND ACCESS TO DRUGS"	117

PART III
REVIEWS FROM THREE INDEPENDENT
EXPERTS SELECTED BY WHO 141

1. REVIEWER A..... 141

2. REVIEWER B..... 161

3. REVIEWER C..... 169